
Marker Therapeutics Partners with Cellipont on MT-601
Key highlights
- MT-601 production to scale via Cellipont’s cGMP capabilities
- Phase 1 APOLLO trial shows 78% response, 44.4% complete response
- Partnership supports future pivotal trial and commercial readiness
- Cellipont’s Texas facility provides modular cleanrooms and advanced QC labs
Source: Globe Newswire
Notable Quotes
“ This exciting collaboration with Cellipont is a critical step forward as we prepare for a potential pivotal trial of MT-601... ”
Dr. Juan Vera, President and CEO at Marker Therapeutics
“ We are proud to support Marker Therapeutics in advancing MT-601, a compelling MAR-T cell therapy... ”
Darren Head, CEO at Cellipont Bioservices
Why This Matters
This collaboration marks a significant stride in the clinical and commercial journey of Marker’s MT-601, a novel MAR-T cell therapy aimed at patients with limited treatment options following CAR-T failure. By partnering with Cellipont Bioservices—a CDMO with scalable, end-to-end manufacturing capabilities—Marker ensures a streamlined path toward pivotal trials and potential market introduction, addressing critical gaps in lymphoma treatment.